Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin and losartan renal hemodynamic crossover study in type 2 diabetes
NL-OMON49031Phase 4Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of empagliflozin and losartan in type 2 diabetes mellitus (T2DM) and diabetic glomerulosclerosis (4 arms), sponsored by Vrije University Medical Center. Primary endpoint: Renal hemodynamics. Started Nov 2020; status: active, not recruiting.
02
Drugs
empagliflozinlosartan
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic glomerulosclerosis
Beyond the preview
Go deeper on NL-OMON49031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49031.